The Medical Letter on Drugs and Therapeutics
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved betrixaban (Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have moderately or severely restricted mobility and other risk factors for VTE. Betrixaban is the first oral anticoagulant to be approved in the US for this indication.

PREVENTION OF VTE – Anticoagulant prophylaxis is recommended for hospitalized, immobilized medical patients with additional risk factors for VTE (e.g., active cancer, history of VTE, obesity). Use of unfractionated heparin, a low-molecular-weight heparin such as enoxaparin (Lovenox, and generics), or the direct factor Xa inhibitor fondaparinux (Arixtra, and generics) has been shown to reduce the risk of fatal pulmonary embolism (PE) by ~60% in such patients. Pharmacologic prophylaxis is not recommended for ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
Article code: 1537b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian